As of May 29, 2025, Regeneron Pharmaceuticals Inc (REGN) reports a ROA (Return on Assets) of 11.69%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Regeneron Pharmaceuticals Inc's ROA (Return on Assets)
Over recent years, Regeneron Pharmaceuticals Inc's ROA (Return on Assets) has shown significant volatility. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | 11.69% |
| 2023-12-31 | 11.95% |
| 2022-12-31 | 14.85% |
| 2021-12-31 | 31.75% |
| 2020-12-31 | 20.47% |
This slight upward trend highlights how Regeneron Pharmaceuticals Inc manages its efficiency in using assets to generate earnings over time.
Comparing Regeneron Pharmaceuticals Inc's ROA (Return on Assets) to Peers
To better understand Regeneron Pharmaceuticals Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Regeneron Pharmaceuticals Inc (REGN) | 11.69% |
| Arena Pharmaceuticals Inc (ARNA) | 33.86% |
| Halozyme Therapeutics Inc (HALO) | 21.52% |
| CureVac NV (CVAC) | 20.20% |
| Alkermes Plc (ALKS) | 17.86% |
| United Therapeutics Corp (UTHR) | 16.23% |
Compared to its competitors, Regeneron Pharmaceuticals Inc's ROA (Return on Assets) is among the highest compared to peers, demonstrating superior efficiency in generating earnings from assets.